Abstract:Currently, hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide; 82% of the cases occur in developing countries, with 55% occurring in China [1]. Liver transplantation (LT), a potentially curative thera peutic modality of HCC, allows radical extirpation of the cancer and restores normal liver function. There is increasing evidence that, in the long term, LT will be the best therapeutic option for cirrhosis-associated HCC [2]. Unfortunately, the recurrence rate is high in HCC patients who undergo LT, which markedly reduces the longterm and medium-term survival of HCC patients [3]. Therefore, risk estimation of post-transplant tumor recurrence is an essential element in selecting a subset of HCC patients for LT. In clinical practice, this risk estimation is based on the number and size of the nodules, and microscopic/macroscopic vascular invasion; and selection criteria for LT have been established to select HCC patients according to these clinical features. The Milan criteria proposed by Mazzaferro and his colleagues – a single lesion of 5 cm or smaller in diameter, or three lesions each smaller than 3 cm in diameter, and without macroscopic vascular invasion – have been accepted worldwide for identifying candidates with good prognosis and low recurrence rates [4]. The Milan criteria were chosen in an attempt to minimize the difference in outcomes between transplanted HCC patients and those who did not have HCC, and these criteria have been adopted for organ allocation in the USA and in Europe [5,6]. Despite their proven utility, many recent data have suggested that these criteria are too restrictive, and many patients with tumor burdens outside the Milan criteria may potentially benefit from LT. Moreover, limiting LT to HCC patients within the Milan criteria may be unjust for those outside of the criteria who could have a favorable outcome with LT. Several expansions of the Milan criteria have been proposed. Yao and coworkers at the University of California, San Francisco (UCSF; CA, USA) reported that LT candidates with a solitary tumor of 6.5 cm in diameter or smaller, or three or fewer nodules with the largest lesion no larger than 4.5 cm in diameter, and a total tumor diameter no larger than 8 cm (the so-called UCSF criteria) achieved excellent results following LT that were not different from those for HCC patients within the Milan criteria [7]. Although the UCSF criteria have been validated by several groups [8], these criteria have not been accepted unanimously, which may be related to the results of a large multi center study that suggested the UCSF criteria to be associated with a 5-year survival rate of less than 50% when applied to preoperative evaluation [9]. In addition, the UCSF criteria allow LT for large tumors, which have been proven to be associated with post-transplant metastatic recurrence [10]. Lastly, both the Milan and the UCSF criteria exclude those patients with more than three nodules, who may obtain good outcomes if the tumors are of a reasonable size. Toso and his colleagues proposed an expansion of the current allocation criteria Zhi Dai, PhD Liver Cancer Institute, Shanghai 200032, PR China dai.zhi@zs-hospital.sh.cn

The Optimal Management for Sub-Centimeter Hepatocellular Carcinoma: Curative Treatments or Follow-Up?

Can Immediately Treating Subcentimeter Hepatocellular Carcinoma Improve The Survival Of Patients?

Surgical Resection Plus Radiofrequency Ablation Versus Radical Surgery for Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Management of Small Hepatocellular Carcinoma:Selection of Surgical Resection or Local Ablative Therapies

Subcentimeter Nodules with Diagnostic Hallmarks of Hepatocellular Carcinoma: Comparison of Pathological Features and Survival Outcomes with Nodules Measuring 1–2 Cm

Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma

Evaluation of the effectiveness of surgical resection and ablation for the treatment of early-stage hepatocellular carcinoma: A retrospective cohort study

[Prognostic Factors Influencing Postoperative Survival in Patients with </= 3 Cm Small Hepatocellular Carcinoma].

[Clinical Treatment of Small Hepatocellular Carcinoma].

Tumor Size and Location Affecting the Treatment Selection for Solitary Small Recurrent Hepatocellular Carcinoma (≤3.0cm) after Initial Hepatectomy.

Comparison of resection, ablation and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤ 5 cm: a retrospective, multicenter, cohort study

Optimizing Stage Of Single Large Hepatocellular Carcinoma A Study With Subgroup Analysis By Tumor Diameter

IDDF2019-ABS-0094 Tumor Size and Location Affecting the Treatment Selection for Solitary Small Recurrent Hepatocellular Carcinoma (≤3.0 Cm) after Initial Hepatectomy

Adjuvant Radiotherapy in Centrally Located Hepatocellular Carcinomas after Hepatectomy with Narrow Margin (<1 Cm): a Prospective Randomized Study.

Molecular Markers and Hepatocellular Carcinoma: Lending a Helping Hand in Liver Transplantation?

Effect of Tumor Size on Cancer-Specific Survival in Small Hepatocellular Carcinoma

Three Decades' Experience In Surgery Of Hepatocellular Carcinoma

Hepatocellular Carcinoma in a Large Medical Center of China over a 10-Year Period: Evolving Therapeutic Option and Improving Survival.

Recommended Ten Years' Follow-Up Strategy for Small Hepatocellular Carcinoma after Radiofrequency Ablation: A Cost-Effectiveness Evaluation

Historical Comparison of Overall Survival after Hepatic Resection for Patients with Large And/or Multinodular Hepatocellular Carcinoma.

Primary treatments for solitary hepatocellular carcinoma ≤ 3 cm: A systematic review and network meta-analysis